Clinical Investigator Development in Solid Tumor Oncology

描述(由申请人提供)：本提案的主要目的是为斯普里格斯博士及其在以患者为中心的研究领域的职业发展活动提供工资支持。斯普里格斯博士目前领导着实体肿瘤小组，有12名初级教员(在受聘的三年内)。他还直接负责每年一名妇科研究员的工作。斯普里格斯博士自己的研究项目的实验假设是，耐药因素由基因表达的转录后调控控制。这项实验室计划由两个计划项目赠款的领导来补充。在卵巢项目中，斯普里格斯博士领导了一个面向临床的项目，该项目与卵巢癌复发后的再次诱导有关，作为他最初包含在卵巢PO1中的RO1的延伸。在癌症化疗项目中，他监督实施了4个项目，分别针对1)HSP90靶向，2)组蛋白脱乙酰酶靶向，3)P53依赖靶向，以及4)MAPK通路抑制。这两个项目与MSKCC UO1一起，构成了临床翻译研究中研究员和初级教员发展的临床研究的基础。这项提议是一个独特的机会，可以培训研究员将转录后耐药的实验室研究与目标新药物的初始临床研究相结合。作为这一计划的一部分，斯普里格斯博士与迪恩·巴约林博士共同担任机构K30临床研究计划的首席研究员，并为一年级研究员和初级教员提供了专门的拨款撰写培训计划。在一个相关的活动中，我们提出了一个新的机制来评估医学肿瘤学教师，并建议收集一个固定的数据集来创建MSKCC初级教师晋升的基准。

DESCRIPTION (provided by applicant): The principal purpose of this proposal is to provide salary support for Dr. Spriggs and his career development activities in the area of patient oriented research. Dr Spriggs currently leads the solid tumor group with 12 junior faculty members (within three years of appointment). He also has direct responsibility for one Gyn Fellow annually. The experimental hypothesis of Dr. Spriggs' own research program is that elements of drug resistance are controlled by post transcriptional regulation of gene expression. This laboratory program is complemented by leadership of two program project grants. In the Ovarian Program, Dr. Spriggs leads a clinically oriented project related to re-induction following relapse in Ovarian cancer as an extension for his RO1 which was initially included in the Ovarian PO1. In the Cancer Chemotherapy Program, he supervises the conduct of 4 projects directed at 1) HSP90 targeting, 2) Histone deacetylase targeting, 3) p53 dependent targeting, and 4) Inhibition of the MAPK kinase pathways. These two programs, along with the MSKCC UO1, form the basis of clinical research for both fellows and junior faculty development in clinical translational research. This proposal represents a unique opportunity to train fellows in the integration of laboratory studies of post transcriptional drug resistance with the initial clinical studies of targeted new agents. As part of this program, Dr Spriggs is the co-principal investigator with Dr. Dean Bajorin of the institutional K30 program for clinical investigation and a specific training program in grant writing is provided for 1st year fellows and for junior faculty members. In a related activity, we propose a novel mechanism for the evaluation of medical oncology faculty and propose to collect a fixed data set to create benchmarks for advancement of junior faculty members at MSKCC.